Serum Institute Of India and Novavax have signed an agreement for development of Novavax’ Covid 19 vaccine candidates in India and other countries. Commericializing 100 crore doses.
We believe that Novavax’ NVX-CoV2373 has significant potential to successfully prevent COVID-19. Given our experience with Novavax on the development of a malaria vaccine, we know the power of their vaccine technologies.We will work urgently together to bring this vaccine to patients in these geographies
CEO of Serum Institute Of India, Adar Poonawala said in a statement.
Novavax and Serum Institute of India are in partnership for producing, commercializing and developing Novavax Vaccine especially in low – middle countries. They will sell these vaccines in these countries and them distribute the profit.
As the world’s largest vaccine manufacturer in terms of doses delivered, Serum Institute is the ideal partner to advance NVX‑CoV2373 throughout India and the low- and middle-income countries. This partnership continues to build on our companies’ collaborative history.
Said Stanley C. Erick, president and CEO of Novavax.
